Core Laboratories (NYSE:CLB) reported Q2 EPS of $0.12, $0.02 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $120.9 million versus the consensus estimate of $121.94 million.
Core Laboratories (NYSE:CLB) reported Q2 EPS of $0.12, $0.02 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $120.9 million versus the consensus estimate of $121.94 million.